U.S. markets closed

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.6200-0.0600 (-2.24%)
At close: 03:59PM EDT
2.6100 -0.01 (-0.38%)
After hours: 04:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.6800
Bid2.1000 x 1100
Ask2.9800 x 800
Day's Range2.4900 - 2.7100
52 Week Range2.4900 - 9.7500
Avg. Volume13,520
Market Cap12.722M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-4.5400
Earnings DateMay 09, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AEZS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aeterna Zentaris Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Zacks

    Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

    Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

    – Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones – Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen™ in the U.S. and Canada TORONTO, ONTARIO, March 23, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)

  • GlobeNewswire

    Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

    Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Pharmanovia, a global lifecycle management healthcare company, has acquired from th